SGLT2 Inhibitors Linked to Cardiorenal Benefits Across CKM Syndrome Stages 2–4
A large analysis of clinical-trial evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors protect the heart and kidneys across multiple stages of cardiovascular-kidney-metabolic disease, including...




